S. Ballard

发表

A comparative study of 1-substituted imidazole and 1,2,4-triazole antifungal compounds as inhibitors of testosterone hydroxylations catalysed by mouse hepatic microsomal cytochromes P-450.

M. Tarbit, S. Ballard, A. Lodola, 1988, Biochemical pharmacology.

Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds.

J. Corbin, I. Turko, S. Francis, 1999, Molecular pharmacology.

The effect of intravenously administered phosphocreatine on ATP and phosphocreatine concentrations in the cardiac muscle of the rat.

L. F. Chasseaud, S. Ballard, W. Down, 1983, Arzneimittel-Forschung.

Regional Hemodynamic Effects of Neutral Endopeptidase Inhibition and Angiotensin (AT1) Receptor Antagonism Alone or in Combination in Conscious Spontaneously Hypertensive Rats

S. Gardiner, T. Bennett, S. Ballard, 2006, Journal of Pharmacology and Experimental Therapeutics.

UK-500,001, a potent selective inhibitor of phosphodiesterase type 4 (PDE4) designed for inhaled delivery, inhibits TNF-a, MIP-1b and LTB4 released from native blood cells.

M. Trevethick, A. Barnard, M. Yeadon, 2007 .

Design and synthesis of long acting inhaled corticosteroids for the treatment of asthma.

David S. Millan, M. Yeadon, P. Glossop, 2011, Bioorganic & medicinal chemistry letters.

The development of non-steroidal dual inhibitors of both human 5α-reductase isozymes

P. Finn, J. Blagg, F. Macintyre, 1996 .

Haemodynamic effects of the selective phosphodiesterase 5 inhibitor, UK‐357,903, in conscious SHR

S. Gardiner, T. Bennett, S. Ballard, 2004, British journal of pharmacology.

Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction.

G. Muirhead, M. J. Allen, S. Ballard, 1996, International journal of impotence research.

Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes.

S. Ballard, A. Naylor, C. Gingell, 1998, The Journal of urology.

The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokinetics.

M. Bunnage, K. Beaumont, D. Leahy, 2012, Bioorganic & medicinal chemistry.

Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro.

G. Angelini, S. Ballard, M. Miller, 1997, British journal of urology.

Effect of the selective phosphodiesterase type 5 inhibitor sildenafil on erectile dysfunction in the anesthetized dog.

S. Ballard, A. Naylor, A. J. Carter, 1998, The Journal of urology.

Hemodynamic Effects of Phosphodiesterase 5 and Angiotensin-Converting Enzyme Inhibition Alone or in Combination in Conscious SHR

S. Gardiner, T. Bennett, S. Ballard, 2005, Journal of Pharmacology and Experimental Therapeutics.

Absorption and elimination of a branched-chain alkylpolyethoxylate surfactant in rats.

D. R. Hawkins, S. Ballard, W. Down, 1983, Toxicology letters.

The insulin-like growth factor type I receptor stimulates growth and suppresses apoptosis in prostatic stromal cells.

F. Habib, S. Ballard, A. Naylor, 1998, The Journal of clinical endocrinology and metabolism.

The effect of caffeine on the absorption of 3H-dihydroergocryptine (DHEC) in the rat.

S. Ballard, W. Down, L. Chasseaud, 1980, Arzneimittel-Forschung.